drug
CLN-049
Phase 1updated 6mo agoby $CGEM Cullinan Therapeutics, Inc.
Phase 1community read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying CLN-049
News(1)
- Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earningsWhen Ionis Pharmaceuticals’ Tryngolza undersold, investors immediately looked to Arrowhead Pharmaceuticals’ executives for answers on how they will navigate a launch in the same market.biospace · 6d ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that